Breast Cancer Metastatic Clinical Trial
Official title:
Identification of Novel Genes Involved in Cancer Cell Extravasation by Transcriptional Profiling of Primary Organ-specific Endothelial Cells and in Vitro 3D Models
The project aims at unraveling the role of organ-specific endothelia mediating the preferential metastasisation of breast cancer cells to bone by using a multi-faceted approach, integrating microfluidics and transcriptomic profiling. Based on a recently study published by the investigators [Jeon et al., PNAS 2015], it can be hypothesized that phenotypic differences at the level of organ-specific endothelial cells are able to drive the preferential extravasation of breast cancer cells to specific sites. Hence, the transcriptional profile of primary organ-specific endothelial cells derived from healthy patients (i.e. non-affected by breast cancer) will be analyzed to identify phenotypic differences between organ-specific populations of endothelial cells. These analyses will allow to identify potential target genes involved in the organ-specific extravasation of cancer cells (i.e. genes differentially expressed by endothelia of preferential and non-preferential metastasisation sites). The selected genes will be silenced and the effect of gene silencing will be evaluated through microfluidic in vitro organ-specific 3D models designed to study cancer cell extravasation.
In particular, the main aim of the study will be to highlight differences between bone and skeletal muscle microenvironments, which are respectively preferential and non-preferential metastasisation sites for breast cancer cells, in order to identify specific pathways driving breast cancer cells extravasation. To this purpose, differences in the transcriptional profile of ECs derived from bone and muscle endothelium will be investigated. These analyses will be used to select target genes differentially expressed by bone- and muscle-specific ECs. Then, ECs obtained from bone and muscle endothelium will be respectively used to mimic bone and muscle microvessel environments in microfluidic in vitro 3D models allowing for the study of breast cancer cell extravasation. The genes selected according to the results of the transcriptomic analysis (e.g. genes expressed in ECs derived from bone endothelium, but not expressed in ECs derived from muscle endothelium) will be silenced and the effect of gene silencing will be evaluated monitoring breast cancer cell extravasation in order to verify the involvement of the selected genes in this process. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04123704 -
Sitravatinib in Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04509596 -
DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04122469 -
The Role of Stereo-tActic BoDy RadIotherApy iN Oligo-Progressive MalignanT Disease
|
N/A | |
| Completed |
NCT03045653 -
Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast Cancer
|
Phase 2 | |
| Terminated |
NCT03322215 -
HR+/HER2- Advanced Breast Cancer and Endocrine Resistance
|
Phase 2 | |
| Active, not recruiting |
NCT04059484 -
Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer
|
Phase 2 | |
| Recruiting |
NCT04368442 -
Cohort Study of Patients With HER2-negative MBC and BRCA 1/2 Pathogenic Mutation
|
||
| Terminated |
NCT03709082 -
Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT03642990 -
NR in Chemo-induced Peripheral Neuropathy
|
Phase 2 | |
| Terminated |
NCT01876251 -
A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04483505 -
Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.
|
Phase 1 | |
| Recruiting |
NCT03086785 -
Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer
|
Phase 2 | |
| Terminated |
NCT04197999 -
A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06439693 -
The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT03638765 -
Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT06100874 -
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
|
Phase 2 | |
| Completed |
NCT05609903 -
Atezolizumab With Nab-paclitaxel for Patients With Triple-negative Stage IV Breast Cancer
|
||
| Active, not recruiting |
NCT04597580 -
Personalised Disease Monitoring in Metastatic Breast Cancer
|
||
| Completed |
NCT05301530 -
Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.
|
Phase 1 | |
| Active, not recruiting |
NCT03328884 -
Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients
|
Phase 2 |